阿司匹林是否会增加接受皮肤损伤切除的患者出血的风险:系统性审查和元分析
Karl A Romain1, David Zargaran2, Alexander Zargaran3
1From the Department of Plastic and Reconstructive Surgery, Chelsea & Westminster Hospital NHS Trust, London, United Kingdom.
Plastic and reconstructive surgery. Global open
|May 13, 2025
概括
服用阿司匹林的患者在皮肤手术后出现术后出血的风险显著增加. 这一系统性审查强调出血的可能性增加,强调在皮肤手术期间考虑使用阿司匹林时需要平衡风险.
科学领域:
- 皮肤病学 皮肤病学
- 手术瘤学手术瘤学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿司匹林是一种常见的药物,可以抑制血小板功能,增加出血风险.
- 皮肤病变切除是恶性瘤,美学或功能常见的程序.
- 在患者管理中,平衡出血风险与停止服用阿司匹林至关重要.
研究的目的:
- 在皮肤外科手术中持续服用阿司匹林与手术后出血风险相关的证据进行系统审查和元分析.
主要方法:
- 按照PRISMA指南进行了系统的文献搜索.
- 包括的研究评估了在接受皮肤外科手术的成年人中出血或血液瘤的发生率.
- 一个随机效应模型计算了各种结果的几率比率,包括出血严重程度.
主要成果:
- 分析了来自20项研究的26,860项手术.
- 发现任何严重性出血 (OR 1.39) 和严重出血 (OR 2.46) 的几率在统计学上显著增加.
- 没有观察到中度出血,感染或伤口脱光的显著增加.
结论:
- 持续服用阿司匹林在接受皮肤手术的患者中显著增加了术后出血的风险.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
417
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
417
Clinical Applications of Epidermal Stem Cells
2.7K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.7K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
568
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
568
Local Anesthetics: Pharmacokinetics
705
The potency and duration of action of local anesthetics (LAs) are determined by their pharmacokinetics. Pharmacokinetics describes how LAs are absorbed, distributed, metabolized, and eliminated from the body. When administered to the vascular tissues, LAs are quickly absorbed and enter the systemic circulation, reducing their localized effects. Adding vasoconstrictors such as epinephrine to LAs reduces their absorption into the systemic circulation, making them clinically effective. The...
705
Extrinsic and Intrinsic Pathways of Hemostasis
4.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
4.2K


